Pathway Medical Partners, LLC
$66.0K 33 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Spinevision SAS
Spinevision SAS reported $65,951.00 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 12 transactions.
- $66.0K Below-median payer
- All-tracks total
- 12 Below-median volume
- Transactions
- 12 Below-median reach
- Recipients
- −$91.4K
- General Payments vs PY2023
Spinevision SAS reported $65,951.00 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1282 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $65,951.00, averaging $5.5K per recipient.
Spinevision SAS's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spinevision-sas Spinevision SAS
$66.0K · #1282/1,925 · 0.0% industry · PY2024
- TOT $66.0K
- RANK #1282
- SHARE 0.0%
- TXN 12
- RCP 12
- CAT 4
- GEN $66.0K
- ΔGEN −$91.4K
- TOP1 73.7%
- PY 2024
Volume peers
Nearest volume peer: Pathway Medical Partners, LLC ($66.0K)
Spinevision SAS sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spinevision SAS's CMS-reported General Payments decreased by $91.4K (−58.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPINEVISION SASPY2023: SPINEVISION SASPY2024: Spinevision SAS. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $157,331.00
- PY2024
- $65,951.00
What the Data Shows for Spinevision SAS
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Spinevision SAS that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $48.4K, accounting for 73.4% of this company's General Payments and 1 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Spinevision SAS's largest category was "Royalty or License" at $48.4K - 73.4% of General Payments.
Spinevision SAS reports 4 general-payment categories - the top three are Royalty or License (73.4%), Travel and Lodging (22.0%), and Consulting Fee (3.0%). The remaining 1 category make up 1.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Spinevision SAS divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $48.4K | 1 | 73.4% |
| Travel and Lodging | $14.5K | 2 | 22.0% |
| Consulting Fee | $2.0K | 1 | 3.0% |
| Food and Beverage | $1.0K | 8 | 1.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $65,641.00 (99.5%) of $65,951.00 in this company's General Payments records across 8 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spinevision SAS
The five named recipients with the highest reported General Payments from this company
- 1
Gary Colon
$48,608.00 across 3 reported transactions
- 2
Pawel Jankowski
$9,966.00 across 2 reported transactions
- 3
Vivek Mehta
$6,730.00 across 2 reported transactions
- 4
Rebecca Kuo
$217.00 across 1 reported transactions
- 5
Hamad Farhat
$120.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Spinevision SAS ranks #1282 of 1,925 by total payments (bottom 33% by spend) but is notably more concentrated than that alone would suggest -- #278 of 1,838 by HHI (top 15% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Spark Therapeutics, Inc. : $1.1M total payments, HHI 5876
- Agile Devices, Inc. : $8.4K total payments, HHI 5847
- Hubly Incorporated : $205.53 total payments, HHI 5839
- New York Blood Center, Inc. : $184.6K total payments, HHI 5838
- Mylan Pharmaceuticals Inc. : $379.70 total payments, HHI 5777
- Novo Nordisk US Research & Development, Inc. : $7.8K total payments, HHI 5774
- Spinevision SAS (this company) : $66.0K total payments, HHI 5765
- Cook Medical LLC : $2.8M total payments, HHI 5718
- Channel Medsystems, Inc. : $194.3K total payments, HHI 5715
- Adagio Medical, Inc. : $49.5K total payments, HHI 5713
- Radical Catheter Technologies, Inc. : $15.2K total payments, HHI 5702
- Halozyme Inc : $56.0K total payments, HHI 5678
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spinevision SAS's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spinevision SAS.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spinevision SAS.
Showing 6 of 1,924 companies with CMS-reported payment data.
Cambridge Interventional LLC
$66.1K 36 recipients
Compare payment profiles
Valinor Pharma, LLC
$65.8K 4,160 recipients
Compare payment profiles
SS White Burs, Inc.
$65.6K 105 recipients
Compare payment profiles
Swan Valley Medical Incorporated
$65.3K 7 recipients
Compare payment profiles
Momentis Surgical Inc.
$66.7K 21 recipients
Compare payment profiles
Put this to use
Spinevision SAS ranks #1282 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Spinevision SAS. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.